| EPA0080 | Effect of combination latency reversing agents and bNAb in SHIV-infected rhesus macaques on antiretroviral therapy | E-poster | Understanding and targeting persistent HIV reservoirs |
| EPA0081 | Transient upregulation of CD4 increases permissibility of Vδ1 T cells to HIV-1 infection | E-poster | Understanding and targeting persistent HIV reservoirs |
| EPA0082 | Molecular deep sequencing analysis of rebound viruses from antiretroviral drug and CRISPR-treated HIV-infected humanized mice | E-poster | Understanding and targeting persistent HIV reservoirs |
| EPA0083 | Engineering macaque B cells for persistent anti-HIV broadly neutralizing antibodies production | E-poster | Novel treatment and prevention strategies |
| EPA0084 | (5R)-5-Hydroxytriptolide inhibits immune activation in SIV-infected ART-treated rhesus macaques | E-poster | Novel treatment and prevention strategies |
| EPA0085 | Dual therapy of Interleukin-21 and anti-α4β7 antibody administration during ART-treated SIV promotes immunological responses and ameliorates dysbiosis in rhesus macaques | E-poster | Novel treatment and prevention strategies |
| EPA0086 | Claisened Hexafluoro treatment ameliorates cognitive deficits in HIV associated neurocognitive disorders (HAND) mice and improves the underlying brain pathogenicity | E-poster | Novel treatment and prevention strategies |
| EPA0087 | Interactions between the local environmental factors within the female reproductive tract in physiological conditions and during Chlamydia trachomatis infection | E-poster | HIV-associated viruses, co-infections and co-morbidities |
| EPA0088 | TB-associated microenvironment represents a barrier for HIV curative strategies | E-poster | HIV-associated viruses, co-infections and co-morbidities |
| EPA0089 | Support vector machine classification modeling identifies composite biomarkers predictive of non-AIDS events in people with HIV on suppressive anti-retroviral therapy | E-poster | HIV-associated viruses, co-infections and co-morbidities |